61.85
price down icon0.74%   -0.46
 
loading
전일 마감가:
$62.31
열려 있는:
$62.32
하루 거래량:
22,622
Relative Volume:
0.51
시가총액:
$1.97B
수익:
-
순이익/손실:
$-32.61M
주가수익비율:
-52.67
EPS:
-1.1742
순현금흐름:
-
1주 성능:
+1.41%
1개월 성능:
+3.64%
6개월 성능:
+4.09%
1년 성능:
+28.53%
1일 변동 폭
Value
$61.01
$62.48
1주일 범위
Value
$59.12
$62.64
52주 변동 폭
Value
$43.70
$86.53

Belite Bio Inc Adr Stock (BLTE) Company Profile

Name
명칭
Belite Bio Inc Adr
Name
전화
-
Name
주소
-
Name
직원
25
Name
트위터
Name
다음 수익 날짜
2025-03-17
Name
최신 SEC 제출 서류
Name
BLTE's Discussions on Twitter

BLTE을(를) 다른 주식과 비교

주식 가격 시가총액 매출 순이익 현금흐름 주당 순 이익
Biotechnology icon
BLTE
Belite Bio Inc Adr
61.85 1.94B 0 -32.61M 0 -1.1742
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
472.27 120.73B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
564.64 61.80B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
328.00 42.46B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
591.74 35.22B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
296.46 31.99B 3.81B -644.79M -669.77M -6.24

Belite Bio Inc Adr Stock (BLTE) Upgrades & Downgrades

날짜 액션 분석자 등급 변경
2023-12-14 개시 Maxim Group Buy
2023-07-28 개시 Cantor Fitzgerald Overweight
2023-07-26 개시 SVB Securities Outperform
2022-08-01 개시 H.C. Wainwright Buy
2022-07-01 개시 The Benchmark Company Buy

Belite Bio Inc Adr 주식(BLTE)의 최신 뉴스

pulisher
Jul 23, 2025

Belite Bio Executives Share Latest Retinal Disease Breakthroughs at BTIG Biotech Conference - Stock Titan

Jul 23, 2025
pulisher
Jul 22, 2025

New Strong Sell Stocks For July 22nd - Barchart.com

Jul 22, 2025
pulisher
Jul 22, 2025

New Strong Sell Stocks for July 22nd - Zacks Investment Research

Jul 22, 2025
pulisher
Jul 19, 2025

What analysts say about Belite Bio Inc Depositary Receipt stockConsistent wealth multiplication - jammulinksnews.com

Jul 19, 2025
pulisher
Jul 16, 2025

Belite Bio concludes enrollment for phase 3 GA trial on oral tinlarebant - Eyes On Eyecare

Jul 16, 2025
pulisher
Jul 16, 2025

Stargardt Disease Pipeline 2025: FDA Approvals and Clinical Trials Landscape with MOA and ROA Highlights by DelveInsight | Nanoscope Therapeutics, Belite Bio, Biophytis, reVision Therapeutics, Inc - The Globe and Mail

Jul 16, 2025
pulisher
Jul 15, 2025

Analysts Offer Insights on Healthcare Companies: Neumora Therapeutics, Inc. (NMRA), Solid Biosciences (SLDB) and Belite Bio, Inc. ADR (BLTE) - The Globe and Mail

Jul 15, 2025
pulisher
Jul 11, 2025

Q2 EPS Estimates for Belite Bio Decreased by Leerink Partnrs - Defense World

Jul 11, 2025
pulisher
Jul 10, 2025

Ouster Announces Date for Second Quarter 2025 Earnings Call - The Globe and Mail

Jul 10, 2025
pulisher
Jul 09, 2025

Belite Bio, Inc.’s Tinlarebant: Promising Treatment for Stargardt Disease with Significant Market Potential - TipRanks

Jul 09, 2025
pulisher
Jul 08, 2025

Phase 3 PHOENIX trial for oral GA treatment completes enrollment - Modern Retina

Jul 08, 2025
pulisher
Jul 03, 2025

Belite Bio stock maintains Buy rating at H.C. Wainwright on trial progress - Investing.com India

Jul 03, 2025
pulisher
Jul 02, 2025

Belite Bio Completes Enrollment for Phase 3 PHOENIX Trial on Tinlarebant - TipRanks

Jul 02, 2025
pulisher
Jul 02, 2025

Major Breakthrough: First-Ever Oral Treatment for Geographic Atrophy Reaches Full Phase 3 Enrollment - Stock Titan

Jul 02, 2025
pulisher
Jun 12, 2025

Analysts Issue Forecasts for Belite Bio FY2026 Earnings - Defense World

Jun 12, 2025
pulisher
Jun 11, 2025

Reviewing Belite Bio (NASDAQ:BLTE) & ZyVersa Therapeutics (NASDAQ:ZVSA) - Defense World

Jun 11, 2025
pulisher
Jun 07, 2025

Bank of America Corp DE Acquires 4,891 Shares of Belite Bio, Inc (NASDAQ:BLTE) - Defense World

Jun 07, 2025
pulisher
Jun 07, 2025

Cohen & Company Inc. (NYSEAMERICAN:COHN) Stock Price Crosses Above Two Hundred Day Moving Average – Here’s What Happened - Defense World

Jun 07, 2025
pulisher
Jun 05, 2025

Belite Bio, Inc (NASDAQ:BLTE) Shares Sold by Citadel Advisors LLC - Defense World

Jun 05, 2025
pulisher
May 31, 2025

BNP Paribas Financial Markets Acquires New Shares in Belite Bio, Inc (NASDAQ:BLTE) - Defense World

May 31, 2025
pulisher
May 24, 2025

What is HC Wainwright’s Forecast for Belite Bio Q1 Earnings? - Defense World

May 24, 2025
pulisher
May 23, 2025

What is HC Wainwright's Estimate for Belite Bio Q2 Earnings? - MarketBeat

May 23, 2025
pulisher
May 22, 2025

Belite Bio stock holds $80 target on FDA breakthrough nod By Investing.com - Investing.com Nigeria

May 22, 2025
pulisher
May 22, 2025

Belite Bio stock holds $80 target on FDA breakthrough nod - Investing.com

May 22, 2025
pulisher
May 22, 2025

Belite Bio’s Promising Outlook: FDA Breakthrough Designation and Upcoming Milestones Boost Buy Rating - TipRanks

May 22, 2025
pulisher
May 21, 2025

Yi Chen Recommends Buy Rating for Belite Bio Due to Breakthrough Therapy Designation and Promising Trial Progress - TipRanks

May 21, 2025
pulisher
May 21, 2025

Why Belite Bio’s Stock is Soaring High - TipRanks

May 21, 2025
pulisher
May 21, 2025

Belite Bio’s Tinlarebant Receives FDA Breakthrough Therapy Designation for Stargardt Disease - TipRanks

May 21, 2025
pulisher
May 21, 2025

Belite Bio Says FDA Grants Breakthrough Therapy Tag to Stargardt Disease Drug - marketscreener.com

May 21, 2025
pulisher
May 21, 2025

Belite Bio Announces FDA Granting Of Breakthrough Therapy Designation For Tinlarebant For The Treatment Of Stargardt Disease - marketscreener.com

May 21, 2025
pulisher
May 21, 2025

Belite Bio Receives FDA Breakthrough Therapy Designation for Tinlarebant in Treating Stargardt Disease - Nasdaq

May 21, 2025
pulisher
May 21, 2025

Belite Bio Announces FDA Granting of Breakthrough Therapy - GlobeNewswire

May 21, 2025
pulisher
May 20, 2025

Analysts Offer Insights on Healthcare Companies: Centessa Pharmaceuticals (CNTA), Arcellx Inc (ACLX) and Belite Bio, Inc. ADR (BLTE) - The Globe and Mail

May 20, 2025
pulisher
May 19, 2025

Q2 Earnings Estimate for Belite Bio Issued By HC Wainwright - Defense World

May 19, 2025
pulisher
May 17, 2025

Belite Bio (NASDAQ:BLTE) Earns “Overweight” Rating from Cantor Fitzgerald - Defense World

May 17, 2025
pulisher
May 17, 2025

HC Wainwright Reaffirms Buy Rating for Belite Bio (NASDAQ:BLTE) - Defense World

May 17, 2025
pulisher
May 16, 2025

Deutsche Bank ADR Virtual Investor Conference: Presentations Now Available for Online Viewing - GlobeNewswire

May 16, 2025
pulisher
May 16, 2025

Benchmark maintains Buy on Belite Bio stock, $80 price target unchanged - Investing.com Nigeria

May 16, 2025
pulisher
May 15, 2025

Belite Bio’s Earnings Call Highlights Clinical Progress and Financial Strength - TipRanks

May 15, 2025
pulisher
May 15, 2025

Belite Bio at Deutsche Bank Conference: Promising Drug Trials By Investing.com - Investing.com India

May 15, 2025
pulisher
May 15, 2025

Transcript : Belite Bio, Inc Presents at Deutsche Bank ADR Virtual Investor Conference, May-15-2025 12 - marketscreener.com

May 15, 2025
pulisher
May 15, 2025

Belite Bio at Deutsche Bank Conference: Promising Drug Trials - Investing.com

May 15, 2025
pulisher
May 15, 2025

Belite Bio stock retains Overweight rating at Cantor Fitzgerald - Investing.com Australia

May 15, 2025
pulisher
May 15, 2025

Belite Bio stock retains Overweight rating at Cantor Fitzgerald By Investing.com - Investing.com India

May 15, 2025
pulisher
May 15, 2025

Promising Clinical Trials and Strategic Developments Justify Buy Rating for Belite Bio - TipRanks

May 15, 2025
pulisher
May 15, 2025

Belite Bio Advances Clinical Trials Amid Financial Challenges - TipRanks

May 15, 2025
pulisher
May 14, 2025

Earnings call transcript: Belite Bio’s Q1 2025 sees narrower EPS loss - Investing.com Nigeria

May 14, 2025
pulisher
May 14, 2025

Earnings Flash (BLTE) Belite Bio Q1 Loss $0.45 Vs. FactSet Est. $0.35 Loss - marketscreener.com

May 14, 2025
pulisher
May 14, 2025

Belite Bio Q1 2025 Earnings Call Transcript - MarketBeat

May 14, 2025
pulisher
May 14, 2025

Belite Bio Advances Tinlarebant Trials with Positive Interim Results - TipRanks

May 14, 2025
pulisher
May 14, 2025

Belite Bio, Inc Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com

May 14, 2025

Belite Bio Inc Adr (BLTE) 재무 분석

매출

loading

순이익

loading

현금흐름

loading

주당 순 이익

loading
$23.63
price up icon 3.32%
$36.59
price up icon 1.61%
$103.52
price up icon 0.08%
$27.57
price down icon 1.57%
$114.57
price down icon 0.03%
biotechnology ONC
$296.46
price up icon 0.55%
자본화:     |  볼륨(24시간):